

JUNE 2025

Date	Headline and Source	Link	Summary
1 st June	Bayer Gets CDSCO Panel Nod To Conduct Phase 3 Trial for Finerenone Medical Dialogues, June 01, 2025	Bayer Gets CDSCO Panel Nod To Conduct Phase 3 Trial for Finerenone	Bayer Pharmaceutical has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial of mineralocorticoid receptor antagonist Finerenone, or BAY 948862.
1 st June	Merck Specialties Launches Two-Minute Action Oral Cancer Self-Check Campaign on World No Tobacco Day BW Healthcare World, June 01, 2025	Merck Specialties Launches Two-Minute Action Oral Cancer Self-Check Campaign on World No Tobacco Day	On World No Tobacco Day, Merck Specialties. unveiled its national Two-Minute Action for Oral Cancer Protection campaign, featuring an innovative mirror-based standee designed to prompt monthly two-minute self-examinations for early signs of oral cancer.
5 th June	Servier India introduces 'Ivosidenib' (Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma The Wire, June 05, 2025	Servier India introduces 'Ivosidenib' (Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma	Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication.
9 th June	CDSCO Panel Approves Bayer's Real-World Use Study for Heart Failure Drug Vericiguat Medical Dialogues, June 09, 2025	CDSCO Panel Approves Bayer's Real-World Use Study for Heart Failure Drug Vericiguat	The proposal, presented during the Cardiovascular SEC meeting held on April 9, 2025, aimed to assess real-world utilization of Vericiguat under Study No. 22613 (Version 1.0, dated September 6, 2024). Vericiguat belongs to a class of drugs known as soluble guanylate cyclase (sGC) stimulators.
9 th June	CDSCO Panel Approves Updated Prescribing Information for AstraZeneca's Rosuvastatin (Crestor) Medical Dialogues, June 09, 2025	CDSCO Panel Approves Updated Prescribing Information for AstraZeneca's Rosuvastatin (Crestor)	The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval for the updated Prescribing Information of Rosuvastatin Calcium Tablets IP 5mg, 10mg, 20mg, and 40mg (Crestor), marketed by AstraZeneca Pharma India Limited.
13 th June	Healthcare on wheels: 2 lakh Nagpurians to get free treatment	Healthcare on wheels: 2 lakh Nagpurians to get free treatment through mobile medical units	As part of a tripartite Memorandum of Understanding (MoU), two Mobile Medical Units (MMUs) have been deployed through

	through mobile medical units Nagpur today, June 13, 2025		a collaborative effort involving Sanofi India Limited, Nagpur Municipal Corporation (NMC), and the Piramal Swasthya Management and Research Institute (PSMRI).
15 th June	Health Talk: Bharat Biotech-GSK's Shigella vaccine candidate holds promise Hindustan Times, June 15, 2025	Health Talk: Bharat Biotech-GSK's Shigella vaccine candidate holds promise	Hyderabad-based Bharat Biotech has partnered with GSK a British multinational pharmaceutical and biotechnology company for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex123, the companies announced in a joint statement on Thursday.
18 th June	Revolutionizing Indian Healthcare: The Impact of Global Research-Based Pharmaceutical Organizations ET Pharma, June 18, 2025	Revolutionizing Indian Healthcare: The Impact of Global Research-Based Pharmaceutical Organizations	India's healthcare landscape is poised for further transformation, and Global research-based pharmaceutical organisations are set to play an instrumental role in unlocking the full potential of this vibrant sector, ensuring better healthcare for millions of people, now and in the future. This article is written by Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI).
19 th June	Abbott, MSD join hands to distribute key diabetic drug across India Business Standard, June 19, 2025	Abbott, MSD join hands to distribute key diabetic drug across India	MSD's sitagliptin and its combinations are marketed in India under the brand names Januvia, Janumet, and Janumet XR. The two American pharmaceutical giants will join hands to leverage Abbott's extensive Indian footprint to distribute this widely used diabetes medication.
19 th June	Boehringer Ingelheim launches three in one poultry vaccine in India The Hindu Business Line, June 19, 2025	Boehringer Ingelheim launches three in one poultry vaccine in India	Boehringer Ingelheim has launched its poultry vaccine in India a single-dose, next-generation solution that protects against Bursal, Newcastle and Marek's disease, the company said. This innovative vaccine is designed to address practical challenges faced by poultry farmers in India, it added, offering early, reliable, and long-lasting immunity with one administration at the hatchery.
20 th June	Decode, Detect, Defeat: National Campaign Puts Spotlight on Sickle Cell Disease Hindustan Times, June 20, 2025	Decode, Detect, Defeat: National Campaign Puts Spotlight on Sickle Cell Disease	India's ambitious drive to eliminate Sickle Cell Disease (SCD) by 2047 is gaining momentum this month with the launch of a national media campaign titled India's Fight Against Sickle Cell: From Awareness to Action. Led by HindustanTimes.com, HealthShots, Novo Nordisk & NASCO, the campaign drives awareness and action on Sickle Cell Disease.

20 th June	Abbott inks pact with MSD Pharma to market diabetes portfolio India Infoline, June 20, 2025	Abbott inks pact with MSD Pharma to market diabetes portfolio	These brands continue to thrive in the DPP4 inhibitor segment, even though a patent has expired in July 2022 that allowed the company to enter the generics market and reached a significant price competition. Sitagliptin was first introduced in India in 2008. It has played a crucial role in managing type 2 diabetes by lowering HbA1c levels and improving blood sugar control.
23 rd June	AstraZeneca's Oral PCSK9 Inhibitor AZD0780 Cleared for Phase III Trial by CDSCO Panel Medical Dialogues, June 23, 2025	AstraZeneca's Oral PCSK9 Inhibitor AZD0780 Cleared for Phase III Trial by CDSCO Panel	The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to AstraZeneca Pharma India Limited to conduct a Phase III clinical trial for its investigational cardiovascular drug AZD0780.
24 th June	Eli Lilly announces trial results for world's 2nd weekly insulin, aims for launch by yearend The Print, June 24, 2025	Eli Lilly announces trial results for world's 2nd weekly insulin, aims for launch by yearend	There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on Monday announced results of its successful late-stage trial of its weekly insulin. As they dramatically simplify treatment for many patients by reducing the frequency of injections from daily or mealtime to weekly, weekly insulin shots are being seen as potential gamechangers for millions of diabetics who need insulin therapy.
25 th June	Novo's weight-loss drug Wegovy hits Indian mkt Business Standard, June 25, 2025	Novo's weight-loss drug Wegovy hits Indian mkt	Danish drugmaker Novo Nordisk has launched its weight-loss drug Wegovy (semaglutide) in India, heating up competition in the country's limited but growing GLP- 1 drug market already buzzing with US giant Eli Lilly's entry. Eli Lilly launched its GLP-1 based therapy Mounjaro (tirzepatide) three months ago. India ranks third globally in overweight and obesity prevalence.
26 th June	Label Update for AstraZeneca's Olaparib Cleared by CDSCO Panel Medical Dialogues, June 26, 2025	Label Update for AstraZeneca's Olaparib Cleared by CDSCO Panel	In a recent regulatory update, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has approved the proposed revision to the prescribing information for Olaparib Tablets 100 mg and 150 mg, submitted by AstraZeneca Pharma India Limited.
27 th June	AstraZeneca invests Rs 166 crore to expand Bengaluru operations	AstraZeneca invests Rs 166 crore to expand Bengaluru operations	Global biopharmaceutical company AstraZeneca is investing Rs166 crore to expand its Bengaluru operations, creating

	The Times of India, June 27, 2025		400 new jobs. The upgraded facility will support around 1,300 employees and enhance the company's capabilities in AI-driven R&D, global business services, IT, and digital health, strengthening its presence in India.
27 th June	Eli Lilly to roll out diabetes medicine in prefilled pen The Economic Times, June 27, 2025	Eli Lilly to roll out diabetes medicine in prefilled pen	US pharmaceutical major Eli Lilly on Thursday announced its plan to launch blockbuster diabetes drug Mounjaro (tirzepatide) in KwikPen, a prefilled pen designed for once-a-week administration for single patients in the Indian market, two days after its rival Danish drug maker Novo Nordisk launched the weight loss drug Wegovy as a weekly injection in the country, intensifying competition in the booming obesity market.
29 th June	Pfizer Gets CDSCO Panel Nod to Conduct Phase IIIb Trial of Rimegepant for Menstrual Migraine Medical Dialogues, June 29, 2025	Pfizer Gets CDSCO Panel Nod to Conduct Phase IIIb Trial of Rimegepant for Menstrual Migraine	The firm had presented the Phase IIIb clinical study protocol No. C4951063 Amendment 1 dated 05 December 2024 for review. The proposal was evaluated during the recent SEC meeting. After detailed deliberation, the committee recommended for grant of permission to conduct the trial as presented by the firm, the SEC noted in its official recommendation.
30 th June	AstraZeneca expands Global Hub in Bangalore with Rs 166 crore investment Medical Dialogues, June 30, 2025	AstraZeneca expands Global Hub in Bangalore with Rs 166 crore investment	AstraZeneca, a global, science led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bangalore. The new facility will house nearly 1300 employees, including 400 new jobs, supporting the company's capabilities in AI-powered innovation across Research and Development, Global Business Services, IT, and Digital Health operations.
